Janux Therapeutics (JANX) Institutional Ownership

75.39% of Janux Therapeutics' stock is owned by institutional investors. Learn more on JANX's institutional investor holdings.

Of the 198 institutional investors that purchased Janux Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Janus Henderson Group PLC ($2.41M), Wellington Management Group LLP ($2.16M), RA Capital Management L.P. ($2.02M), State Street Corp ($1.96M), Prosight Management LP ($1.66M), Adage Capital Partners GP L.L.C. ($1.58M), and Alyeska Investment Group L.P. ($1.25M).

Institutional investors have bought a total of 15,395,641 shares in the last 24 months. This purchase volume represents approximately $249.81M in transactions.

Of the 65 institutional investors that sold Janux Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Adage Capital Partners GP L.L.C. ($3.50M), Janus Henderson Group PLC ($1.15M), Orbimed Advisors LLC ($970.83K), Readystate Asset Management LP ($850.95K), Franklin Resources Inc. ($801.18K), Perceptive Advisors LLC ($677.73K), and Price T Rowe Associates Inc. MD ($521.09K).

Institutional investors have sold a total of 13,387,039 shares in the last 24 months. This volume of shares sold represents approximately $238.60M in transactions.